Metozolv label has new tardive dyskinesia warning
The new chewable heartburn medication Metozolv, an orally disintegrating version of Reglan (metoclopramide), has added a warning to its label alerting users of a risk of the serious movement disorder Tardive Dyskinesia with long-term use of the drug. The change to the drug’s safety label was approved by the Food and Drug Administration (FDA) and announced this month.


It might surprise some to learn that the prescription heartburn drug
Dawn Harris says she was never made aware that long-term use of the acid reflux drug